RECORD-2: Phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma

Ravaud A.Barrios C.H.Alekseev B.Tay M.-H.Agarwala S.S.Yalcin S.CHIA-CHI LINRoman L.Shkolnik M.Anak O.Gogov S.Pelov D.Louveau A.-L.Melichar B.2022-09-152022-09-1520150923-7534https://www.scopus.com/inward/record.uri?eid=2-s2.0-84937900491&doi=10.1093%2fannonc%2fmdv170&partnerID=40&md5=a0be19b0985cc38febc8c1032d9a332fhttps://scholars.lib.ntu.edu.tw/handle/123456789/620303RECORD-2: Phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomajournal article10.1093/annonc/mdv170258516322-s2.0-84937900491